New perspectives in nanotherapeutics for chronic respiratory diseases

Biophysical Reviews

Volumn 9, Issue 5, 2017, Pages 793-803

  da Silva, Adriana Lopes ^a   Cruz, Fernanda Ferreira ^a   Rocco, Patricia Rieken Macedo ^a   Morales, Marcelo Marcos ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Lung diseases; Nanomedicine; Nanoparticles; Nanotherapy

Indexed keywords

AMIKACIN; BERAPROST; CD86 ANTIGEN; ENDOTHELIN RECEPTOR ANTAGONIST; FIBROBLAST GROWTH FACTOR; GLYCERYL TRINITRATE; INTERLEUKIN 1BETA; NANOPARTICLE; PITAVASTATIN; TOBRAMYCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ASTHMA; BIOCOMPATIBILITY; BRONCHUS OBSTRUCTION; CD4+ T LYMPHOCYTE; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; HEAVY METAL POISONING; HUMAN; LUNG EMPHYSEMA; MESENCHYMAL STROMA CELL; MUCOCILIARY CLEARANCE; NANOMEDICINE; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL LUNG DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SILICOSIS; SPIROMETRY; TH2 CELL; TUMOR MICROENVIRONMENT;

EID: 85032184107     PISSN: 18672450     EISSN: 18672469     Source Type: Journal    
DOI: 10.1007/s12551-017-0319-x     Document Type: Review

References (112)

1. Ahmad Z, Sharma S, Khuller GK (2005) Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 26(4):298–303
2. Akagi S, Nakamura K, Matsubara H et al (2016) Intratracheal administration of prostacyclin analogue-incorporated nanoparticles ameliorates the development of monocrotaline and sugen-hypoxia-induced pulmonary arterial hypertension. J Cardiovasc Pharmacol 67(4):290–298
3. Akagi S, Nakamura K, Miura D et al (2015) Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension. Int Heart J 56(3):354–359
4. Al Faraj A, Shaik AS, Afzal S et al (2014) MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int J Nanomedicine 9:1491–1503
5. Ali W, Moghaddam FJ, Raza MU et al (2016) Electromechanical transducer for rapid detection, discrimination and quantification of lung cancer cells. Nanotechnology 27(19):195101
6. Alton EW, Armstrong DK, Ashby D et al (2015) Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3(9):684–691
7. Amirfazli A (2007) Nanomedicine: magnetic nanoparticles hit the target. Nat Nanotechnol 2(8):467–468
8. Anselmo AC, Mitragotri S (2014) An overview of clinical and commercial impact of drug delivery systems. J Control Release 190:15–28
9. Ardekani S, Scott HA, Gupta S et al (2015) Nanoliposomal nitroglycerin exerts potent anti-inflammatory effects. Sci Rep 5:16258
10. Azzazy HM, Mansour MM, Kazmierczak SC (2007) From diagnostics to therapy: prospects of quantum dots. Clin Biochem 40(13–14):917–927
11. Barnes PJ (2012) Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol 129(1):48–59
12. Bhavna, Ahmad FJ, Mittal G et al (2009) Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm 71(2):282–291
13. Bivas-Benita M, Lin MY, Bal SM et al (2009) Pulmonary delivery of DNA encoding mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 27(30):4010–4017
14. Boylan NJ, Kim AJ, Suk JS et al (2012a) Enhancement of airway gene transfer by DNA nanoparticles using a pH-responsive block copolymer of polyethylene glycol and poly-L-lysine. Biomaterials 33(7):2361–2371
15. Boylan NJ, Suk JS, Lai SK et al (2012b) Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation. J Control Release 157(1):72–79
16. Brenner JS, Bhamidipati K, Glassman PM et al (2017) Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine 13(4):1495–1506
17. Caplen NJ, Alton EW, Middleton PG et al (1995) Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1(1):39–46
18. Chen HW, Su SF, Chien CT et al (2006) Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J 20(13):2393–2395
19. Chen L, Nakano K, Kimura S et al (2011) Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 57(2):343–350
20. Chen X, Huang W, Wong BC et al (2012) Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine 7:1139–1148
21. Cooper V, Metcalf L, Versnel J et al (2015) Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med 25:15026
22. Cuccarese MF, Dubach JM, Pfirschke C et al (2017) Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. Nat Commun 8:14293
23. da Silva AL, Martini SV, Abreu SC et al (2014) DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma. J Control Release 180:125–133
24. da Silva AL, Santos RS, Xisto DG et al (2013) Nanoparticle-based therapy for respiratory diseases. An Acad Bras Cienc 85(1):137–146
25. Depreter F, Pilcer G, Amighi K (2013) Inhaled proteins: challenges and perspectives. Int J Pharm 447(1–2):251–280
26. Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 14(2):282–295
27. Di Gioia S, Trapani A, Castellani S et al (2015) Nanocomplexes for gene therapy of respiratory diseases: targeting and overcoming the mucus barrier. Pulm Pharmacol Ther 34:8–24
28. Digesu CS, Hofferberth SC, Grinstaff MW, Colson YL (2016) From diagnosis to treatment: clinical applications of nanotechnology in thoracic surgery. Thorac Surg Clin 26(2):215–228
29. Dwivedi MV, Harishchandra RK, Koshkina O et al (2014) Size influences the effect of hydrophobic nanoparticles on lung surfactant model systems. Biophys J 106(1):289–298
30. Emerich DF, Snodgrass P, Lafreniere D et al (2002) Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res 19(7):1052–1060
31. Fain SB, Panth SR, Evans MD et al (2006) Early emphysematous changes in asymptomatic smokers: detection with 3He MR imaging. Radiology 239(3):875–883
32. Geiser M, Quaile O, Wenk A et al (2013) Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Part Fibre Toxicol 10:19
33. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2017) Global strategy for the diagnosis, management, and prevention of COPD
34. González-García I, Solé RV, Costa J (2002) Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci U S A 99(20):13085–13089
35. Grenier PA, Fetita CI, Brillet PY (2016) Quantitative computed tomography imaging of airway remodeling in severe asthma. Quant Imaging Med Surg 6(1):76–83
36. Günday Türeli N, Türeli AE, Schneider M (2016) Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: design of experiments approach. Int J Pharm 515(1–2):343–351
37. Gupta P, Vermani K, Garg S (2002) Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 7(10):569–579
38. Gupta V, Gupta N, Shaik IH et al (2013) Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J Control Release 167(2):189–199
39. Heijerman H, Westerman E, Conway S et al (2009) Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 8(5):295–315
40. Holloway JW, Yang IA, Holgate ST (2010) Genetics of allergic disease. J Allergy Clin Immunol 125(2 Suppl 2):S81–S94
41. Ishihara T, Hayashi E, Yamamoto S et al (2015) Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension. J Control Release 197:97–104
42. Iyer R, Hsia CC, Nguyen KT (2015) Nano-therapeutics for the lung: state-of-the-art and future perspectives. Curr Pharm Des 21(36):5233–5244
43. Jackson JK, Zhang X, Llewellen S, Hunter WL, Burt HM (2004) The characterization of novel polymeric paste formulations for intratumoral delivery. Int J Pharm 270(1–2):185–198
44. Ju J, Li R, Gu S et al (2014) Impact of emphysema heterogeneity on pulmonary function. PLoS One 9(11):e113320
45. Kenyon NJ, Bratt JM, Lee J et al (2013) Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation. PLoS One 8(10):e77730
46. Key J, Leary JF (2014) Nanoparticles for multimodal in vivo imaging in nanomedicine. Int J Nanomedicine 9:711–726
47. Kim SH, Ye YM, Lee HY, Sin HJ, Park HS (2011) Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther 36(3):399–405
48. Kimura S, Egashira K, Chen L et al (2009) Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 53(5):877–883
49. Kolte A, Patil S, Lesimple P, Hanrahan JW, Misra A (2017) PEGylated composite nanoparticles of PLGA and polyethylenimine for safe and efficient delivery of pDNA to lungs. Int J Pharm 524(1–2):382–396
50. Kong WH, Lee WJ, Cui ZY et al (2007) Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. Biomaterials 28(36):5555–5561
51. Kong X, Hellermann GR, Zhang W et al (2008) Chitosan interferon-gamma nanogene therapy for lung disease: modulation of T-cell and dendritic cell immune responses. Allergy Asthma Clin Immunol 4(3):95–105
52. Köping-Höggård M, Tubulekas I, Guan H et al (2001) Chitosan as a nonviral gene delivery system. Structure–property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther 8(14):1108–1121
53. Kumar M, Kong X, Behera AK et al (2003) Chitosan IFN-gamma-pDNA nanoparticle (CIN) therapy for allergic asthma. Genet Vaccines Ther 1(1):3
54. Kuzmov A, Minko T (2015) Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release 219:500–518
55. Lawani MA, Zongo F, Breton MC et al (2017) Factors associated with adherence to asthma treatment with inhaled corticosteroids: a cross-sectional exploratory study. J Asthma (in press)
56. Lee HY, Mohammed KA, Nasreen N (2016) Nanoparticle-based targeted gene therapy for lung cancer. Am J Cancer Res 6(5):1118–1134
57. Lee Y, Thompson DH (2017) Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(5)
58. Letsou GV, Safi HJ, Reardon MJ et al (1999) Pharmacokinetics of liposomal aerosolized cyclosporine a for pulmonary immunosuppression. Ann Thorac Surg 68(6):2044–2048
59. Lin G, Ouyang Q, Hu R et al (2015) In vivo toxicity assessment of non-cadmium quantum dots in BALB/c mice. Nanomedicine 11(2):341–350
60. Loira-Pastoriza C, Todoroff J, Vanbever R (2014) Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 75:81–91
61. Löndahl J, Jakobsson JK, Broday DM, Aaltonen HL, Wollmer P (2017) Do nanoparticles provide a new opportunity for diagnosis of distal airspace disease? Int J Nanomedicine 12:41–51
62. Lopes-Pacheco M, Bandeira E, Morales MM (2016) Cell-based therapy for silicosis. Stem Cells Int 2016:5091838
63. Mall MA, Galietta LJ (2015) Targeting ion channels in cystic fibrosis. J Cyst Fibros 14(5):561–570
64. Manunta MD, Tagalakis AD, Attwood M et al (2017) Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis. Sci Rep 7(1):700
65. Mastorakos P, da Silva AL, Chisholm J et al (2015) Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A 112(28):8720–8725
66. Matsuo Y, Ishihara T, Ishizaki J et al (2009) Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol 260(1):33–38
67. McLendon JM, Joshi SR, Sparks J et al (2015) Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J Control Release 210:67–75
68. Merdan T, Callahan J, Petersen H et al (2003) Pegylated polyethylenimine-Fab′ antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. Bioconjug Chem 14(5):989–996
69. Merkel OM, Beyerle A, Beckmann BM et al (2011a) Polymer-related off-target effects in non-viral siRNA delivery. Biomaterials 32(9):2388–2398
70. Merkel OM, Urbanics R, Bedocs P et al (2011b) In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Biomaterials 32(21):4936–4942
71. Mohamed NA, Ahmetaj-Shala B, Duluc L et al (2016) A new NO-releasing nanoformulation for the treatment of pulmonary arterial hypertension. J Cardiovasc Transl Res 9(2):162–164
72. Moreau-Marquis S, Stanton BA, O’Toole GA (2008) Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther 21(4):595–599
73. Moreno-Sastre M, Pastor M, Esquisabel A et al (2016) Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm 498(1–2):263–273
74. Muralidharan P, Hayes D Jr, Black SM, Mansour HM (2016) Microparticulate/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2/Keap-1 pathway. Mol Syst Des Eng 1(1):48–65
75. Murdoch JR, Lloyd CM (2010) Chronic inflammation and asthma. Mutat Res 690(1–2):24–39
76. Naikwade SR, Bajaj AN, Gurav P, Gatne MM, Singh Soni P (2009) Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. AAPS PharmSciTech 10(3):993–1012
77. Nakamura K, Matsubara H, Akagi S et al (2017) Nanoparticle-mediated drug delivery system for pulmonary arterial hypertension. J Clin Med 6(5)
78. Nelsen LM, Kimel M, Murray LT et al (2017) Qualitative evaluation of the St George’s respiratory questionnaire in patients with severe asthma. Respir Med 126:32–38
79. Nguyen MM, Carlini AS, Chien MP et al (2015) Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction. Adv Mater 27(37):5547–5552
80. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B (2003) Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52(6):981–986
81. Paranjpe M, Müller-Goymann CC (2014) Nanoparticle-mediated pulmonary drug delivery: a review. Int J Mol Sci 15(4):5852–5873
82. Pascual RM, Peters SP (2005) Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 116(3):477–486; quiz 487
83. Patil-Gadhe, Kyadarkunte, Patole, Pokharkar et al (2014) Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. Eur J Pharm Biopharm 88(1):169–77
84. Patil-Gadhe, Pokharkar (2014) Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur J Pharm Biopharm 88(1):160–8
85. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760
86. Peters SP, Ferguson G, Deniz Y, Reisner C (2006) Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 100(7):1139–1151
87. Raissy HH, Kelly HW, Harkins M, Szefler SJ (2013) Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 187(8):798–803
88. Rangger C, Helbok A, Sosabowski J et al (2013) Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. Int J Nanomedicine 8:4659–4671
89. Ratjen F, Brockhaus F, Angyalosi G (2009) Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 8(6):361–369
90. Riordan JR, Rommens JM, Kerem B et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066–1073
91. Roulet A, Armand L, Dagouassat M et al (2012) Intratracheally administered titanium dioxide or carbon black nanoparticles do not aggravate elastase-induced pulmonary emphysema in rats. BMC Pulm Med 12:38
92. Rudolph C, Lausier J, Naundorf S, Müller RH, Rosenecker J (2000) In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J Gene Med 2(4):269–278
93. Sadeghi L, Yousefi Babadi V, Espanani HR (2015) Toxic effects of the Fe2O3 nanoparticles on the liver and lung tissue. Bratisl Lek Listy 116(6):373–378
94. Salem AK (2014) A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies. Immunotherapy 6(11):1161–1163
95. Salmaso S, Caliceti P (2013) Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv 2013:374252
96. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J (2009) Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev 61(2):115–127
97. Schneider CS, Xu Q, Boylan NJ et al (2017) Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv 3(4):e1601556
98. Sharma K, Somavarapu S, Colombani A, Govind N, Taylor KM (2013) Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery. Int J Pharm 455(1–2):241–247
99. Shinoda K, Hirahara K, Nakayama T (2017) Maintenance of pathogenic Th2 cells in allergic disorders. Allergol Int 66(3):369–376
100. Silva LH, da Silva JR, Ferreira GA et al (2016) Labeling mesenchymal cells with DMSA-coated gold and iron oxide nanoparticles: assessment of biocompatibility and potential applications. J Nanobiotechnol 14(1):59
101. Stocke NA, Arnold SM, Hilt JZ (2015) Responsive hydrogel nanoparticles for pulmonary delivery. J Drug Deliv Sci Technol 29:143–151
102. Suk JS, Lai SK, Wang YY et al (2009) The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 30(13):2591–2597
103. Uddin MJ, Werfel TA, Crews BC et al (2016) Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer. Biomaterials 92:71–80
104. van Rijt SH, Bein T, Meiners S (2014) Medical nanoparticles for next generation drug delivery to the lungs. Eur Respir J 44(3):765–774
105. Vestbo J, Hurd SS, Agustí AG et al (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187(4):347–365
106. Vij N (2011) Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential. Expert Opin Drug Deliv 8(9):1105–1109
107. Wacker M (2013) Nanocarriers for intravenous injection—the long hard road to the market. Int J Pharm 457(1):50–62
108. Wahajuddin, Arora S (2012) Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine 7:3445–3471
109. Wang J, Ben-Jebria A, Edwards DA (1999) Inhalation of estradiol for sustained systemic delivery. J Aerosol Med 12(1):27–36
110. Wang J, Chen Y, Chen B et al (2010) Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int J Nanomedicine 5:861–866
111. Wang W, Zhu R, Xie Q et al (2012) Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 7:3667–3677
112. Xie J, Huang J, Li X, Sun S, Chen X (2009) Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 16(10):1278–1294